Quality of Life Kinoko Platinum AHCC 750 Mg 60 Ct by Quality of Life

Product Information

Conclusion: Results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to eliminate persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize success for durable outcomes. The suppression of the IFN-β level to less than 20 pg/ml correlated with clearance of HPV infections and merits further evaluation as a clinical tool for monitoring patients with HPV infections. In traditional Chinese medicine, mushrooms have been used to modify immunity,” says Dr Kohei Homma, AminoUp’s executive senior director of business development. “Our research scientists were motivated to understand the immunological benefit of mushrooms.” Previously, the two pilot studies evaluating AHCC supplementation in women with persistent HR-HPV infections identified that IFN-β levels of less than 20 pg/ml correlated with the elimination of HR-HPV ( 17). This phase II study confirmed the correlation between suppressed IFN-β levels to less than 20 pg/ml with an increase in T lymphocytes and IFN-γ, which ultimately resulted in clearance of HPV infections in women who received AHCC supplementation. In those patients who were HPV RNA/HPV DNA negative after 6 months of AHCC supplementation but had a mean IFN-β level greater than 20 pg/ml, two remained HPV RNA negative but HPV DNA positive, and three were both HPV RNA and HPV DNA positive 3 months later after supplementation had been stopped. This identified the opportunity for future research to optimize and personalize the duration of supplementation on both HPV infection status and the target IFN-β level. In addition, the data from this study identified the potential opportunity to employ monitoring IFN-β levels, which could be used for both men and women with HPV infections. While this study did focus on women with HR-HPV infections, in the absence of effective testing tools for HPV status in men and with a safety profile comparable to placebo, the use of AHCC supplementation for men with known exposure to HR-HPV (i.e., partners of women with HR-HPV) as well as those with LR-HPV infections could consider AHCC supplementation to clear the HPV infection.

This phase II study was supported by preclinical in vitro studies, in vivo animal studies, and two pilot studies that determined the mechanism of action and confirmed the benefits of AHCC supplementation to eliminate persistent HPV infections. The major strength of this study is that even though AHCC is not a traditional drug intervention, the benefits of AHCC supplementation were held to the traditional efficacy test of a double-blind, randomized, placebo-controlled trial. Unlike many nutritional supplement studies, this study did look at specific immune markers to confirm the mechanism of AHCC modulation of host immune function. Due to limited funding resources, this study could not explore all possible mechanisms of immune modulation that may have supported clearance of the persistent HPV infections. Since the hypothesis of AHCC benefits is based upon modulation of the host immune function, specific HPV typing was not included in this study, which needs to be evaluated closer in future studies. These statements have not been evaluated by any official health authority. These products are not intended to diagnose, treat, cure, or prevent any disease. In conclusion, the results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to clear persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize durable outcomes based on both HPV infection status and the target IFN-β level. Data Availability StatementAminoUp’s vision is to see AHCC become a household name as a daily nutritional supplement for immune maintenance. Currently, AHCC is shipped to an estimated 150,000 people in 40 countries worldwide, and demand is growing. The human papillomavirus (HPV) is classified as a non-enveloped, double-stranded DNA virus that generally infects the epithelial layer of cells including cutaneous and mucosal surfaces and is associated with benign warts, carcinoma in situ, and malignant lesions ( 1, 2). There are over 100 HPV strains identified in humans, 40 low-risk HPV (LR-HPV) strains associated with genital warts/lesions, and fifteen high-risk HPV (HR-HPV) strains associated with cancer. When HR-HPV infections persist over time, patients have an increased risk of developing cancer ( 3). However, it should be noted that having a persistent high-risk HPV infection does not cause cancer by itself; rather, it is a contributing co-factor in the risk for development of cancer when it occurs in combination with other insults such as poor nutrition, smoking, physiological stress, or immune dysfunction/suppression. In the United States, there are an estimated 85,890 cases of cancer caused by persistent high-risk HPV infections, and an estimated 79 million Americans are infected with HPV today ( 4, 5).

Worldwide, cervical cancer is the fourth most common malignancy in women and a major cause of morbidity and mortality ( 1). It accounts for nearly 10% of all cancers, and ~265,700 women die from this disease every year worldwide ( 1). The etiology of cervical cancer has been identified and confirmed associated with high risk-human papillomavirus (HR-HPV) ( 2– 5). The human papillomavirus (HPV) is classified as a non-enveloped, double stranded DNA virus that generally infects the epithelial layer of cells including cutaneous and mucosal surfaces and associated with benign warts, carcinoma in situ and ultimately malignant lesions ( 6, 7). When HR-HPV infections persist overtime, patients have an increased risk of developing cervical cancer ( 8). EXTRACTED, 3RD PARTY TESTED. Alcohol and hot water extraction techniques are used to draw out both the water-soluble and the non-water-soluble bio actives. Many supplement companies claim their products are 3rd party tested but are vague about what is actually tested for and often cannot provide supporting documents. Our Mushroom Complex 6 is 3rd party tested for both heavy metals and active compounds at 2 of Europe's top testing facilities, certificates available upon request.Fucoidan from Wakame seaweed is the most trusted source of Fucoidan available and has been researched and proven in promoting a huge array of health benefits. Brown seaweeds that are rich in Fucoidan have long been eaten each day as part of the Okinawan Diet; a Japanese island that has the longest life expectancy of any native population. AHCC is a proprietary, standardized extract of cultured lentinula edodes mycelia (AHCC ®, Amino Up, Ltd., Sapporo, Japan) that was developed in Japan in 1992; the compound is primarily composed of α-glucan components. Several animal and human studies have reported a variety of therapeutic effects, including antioxidant and anticancer activities and modulation of the immune system to prevent the infectious processes of both viral and bacterial infections ( 9– 14). In clinical studies, AHCC has demonstrated the benefit to decrease the risk of infection and ameliorate symptoms of existing infections ( 11). This phase II study confirmed findings from the two previous pilot studies that demonstrated that AHCC supplementation will modulate the host immune system to eliminate persistent high-risk HPV infections ( 14). While it may not help all patients, in the absence of other systemic treatments, clinicians can recommend AHCC, which is a readily available nutritional supplement that offers a good chance of clearance of persistent HPV infections. If you breach these conditions and we take no action, we will still be entitled to use our rights and remedies in any other situation where you breach these conditions. Governing Law and Jurisdiction

Women must have had 2 other HPV-positive tests with normal/negative cytology, atypical cells, ASCUS, or CIN1 or CIN2 cervical dysplasia History of myocardial infarction within past 6 months, unstable angina, CHF, or uncontrolled hypertension (>140/90). There are limited effective treatment options for clearing HR-HPV infections; majority being local treatment modalities is to alleviate symptoms and remove symptomatic lesions that often reoccur. Fortunately, most HR-HPV infections are cleared within 6–18 months on their own without interventions; only ~10% of women will suffer from persistent HR-HPV infections ( 15, 24). To date, there is no readily available effective systemic interventions to clear HR-HPV infections. Currently prevention of HR-HPV infections with the HPV vaccine nine-valent product before exposure to HPV has demonstrated the best potential for eliminating HR-HPV infections. However, these vaccines have little benefit in those already infected with HR-HPV infections. The human immune system begins to weaken at about 25 years of age, which perhaps could be the contributing factor to why persistent HPV infections are most often observed in women over the age of 30 or with other immunosuppressive conditions. Objective: To determine the efficacy, safety, and durability of the use of AHCC supplementation for 6 months to support the host immune system to clear high-risk human papillomavirus (HPV) infections. The AHCC supplement is a proprietary, standardized extract of cultured lentinula edodes mycelia (AHCC ®, Amino Up, Ltd., Sapporo, Japan) that has been shown to have unique immune modulatory benefits.The primary outcome of this trial was to evaluate clearance of persistent high-risk HPV infection determined by HPV DNA-negative test results achieved while receiving AHCC supplementation and maintained for 3, 6, and 12 months post-completion of the AHCC supplementation compared to receiving placebo. At 12 months, after receiving AHCC supplementation for 6 months, if patients were still HPV DNA positive, it was considered a treatment failure or no response (NR), and they went off study. If negative after completion of 6 months of AHCC supplementation and 6 months of placebo, patients continued on study for another 6 months (two visits) to confirm they remained HPV negative and to evaluate the durability of the response. A complete response (CR) was defined as those patients who were HPV RNA and HPV DNA negative at the time of completion of AHCC supplementation and remained HPV RNA and HPV DNA negative throughout the 12 months of follow-up off AHCC supplementation. A partial response (PR) was defined as those patients who were HPV RNA and HPV DNA negative at the time of completion of AHCC supplementation but then tested either HPV RNA or HPV DNA positive at one or more visits in the 12 months of follow-up off AHCC supplementation. Group 2 served as the control for all time points for the duration of the study. Safety and efficacy data were collected in the patients who elected to continue on unblinded AHCC supplementation for 6 months. Sample Collection and Processing AHCC is able to modulate and improve the non-specific immune functions in our body to a range of risk factors,” says Homma. All patients enrolled were included in safety analysis for adverse events. Overall, no study patients reported greater than grade 1 toxicity on either placebo or the AHCC supplement arm. AHCC was well tolerated compared to placebo.